Trial Details

ACTIVE_NOT_RECRUITING
Basic Information
Clinical ID c988
Identifier NCT05785715
Trial Title Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Ulcerative Colitis
Interventions DRUG: NX-13 250mg|DRUG: NX-13 750mg|DRUG: NX-13 Placebo
Participant Information
Sponsor AbbVie
City Miami
Country/Region United States
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE2
Time Information
Start Date 2023-04-24
Primary Completion Date 2025-12-31
Completion Date 2025-12-31